The anti-inflammatory therapeutics market is expected to be valued at around 127.5 billion USD by 2030 as more people battle through the pain barrier on a daily basis. Inflammation results from tissue injury which initiates the recruitment of immune cells and mediator release. It is the body’s way of initiating the healing process following injury. Inflammation represents a key biological process and, as such, occurs not only in response to infection but also to a diverse range of disease states such as cancer and diabetes. It is well-established that inflammation whether attributable to autoimmunity (e.g. rheumatoid arthritis; RA) or chemical mediators (e.g. gout) causes nociceptive pain.

Acute and chronic inflammatory pain models have been used routinely by the pharmaceutical industry to provide information that helps to guide strategic decision-making around the mechanism of action and efficacy of molecules targeting inflammatory pain as well as providing robust pharmacodynamic end-points.

Examples of models we offer:

  • CFA / carrageenan / capsaicin / formalin induced local inflammatory pain
  • MIA / CFA osteoarthritis joint pain
  • Acute mechanistic pain models (e.g. NGF)
  • Ultraviolet light (UV) burn
  • LPS-induced inflammation (cytokine and chemokine release)

Examples of end points:

  • Weight-bearing (mechanical hypersensitivity)
  • Hargreaves (thermal hyperalgesia)
  • Hot/cold plate (allodynia)
  • Von Frey hairs (tactile allodynia)
  • Randall Selitto (tactile hyperalgesia)
  • Plethysmometer (paw volume)
  • LABORAS automated complex behavioural assessment (e.g. locomotor activity)
  • EEG/sleep
  • Inflammatory cytokine analysis (e.g. synovial fluid markers)
  • PK sampling